Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07349797 · ClinicalTrials.gov registry record · NA
MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure
A NA study, sponsored by MediBeacon.
- Not yet
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT07349797 is a NA study that has not yet begun recruiting, run by MediBeacon. The registered enrollment target is 15 participants.
The verdict
NCT07349797, a NA study, has not yet begun recruiting, sponsored by MediBeacon.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the accuracy and feasibility of transdermal glomerular filtration rate (tGFR) assessment using relmapirazin (Lumitrace) and the MediBeacon tGFR system compared to plasma clearance measurement of GFR in adults with heart failure. The main question it aims to answer is the comparison of the transdermal-derived GFR for each participant using the MediBeacon tGFR to their nGFRBSA measurement. Participants will participate in a Screening visit that will take place within 15 days of the scheduled administration of Lumitrace and iohexol. On dosing day, participants will have the tGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. Following an injection of Lumitrace and iohexol and the initiation of GFR assessments, participants will be followed at the study center for 10-24 hours. All participants will participate in a follow-up phone call approximately 7 days after the last exposure to Lumitrace and iohexol. Researchers will analyze the results to compare the tGFR values to the nGFRBSA measurements for each participant.
Interventions
- DRUG Iohexol
- DEVICE Lumitrace
- DEVICE MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07349797
The ClinicalTrials.gov registry entry for NCT07349797 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediBeacon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Iohexol is the first listed.
NCT07349797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07349797 about?
NCT07349797 is a clinical study titled "MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure". The goal of this clinical trial is to evaluate the accuracy and feasibility of transdermal glomerular filtration rate (tGFR) assessment using relmapirazin (Lumitrace) and the MediBeacon tGFR system compared to plasma clearance measurement of GFR in adults with heart failure. The main question it ai...
What is the current status of trial NCT07349797?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2026-04. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07349797?
The interventions under investigation include: Iohexol (DRUG), Lumitrace (DEVICE), MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR) (DEVICE).
Who is sponsoring clinical trial NCT07349797?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.